Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
TORONTO, March 25, 2026 (GLOBE NEWSWIRE) -- Colliers International Group Inc. (NASDAQ and TSX: CIGI) ("Colliers" or the “Company”) today announced the completion of a private placement of C$550...
-
SAN DIEGO, March 25, 2026 (GLOBE NEWSWIRE) -- Kratos Defense & Security Solutions, Inc. (Nasdaq: KTOS), a Technology, Hardware, Products, System and Software Company addressing the Defense,...
-
DOVER, USA, March 25, 2026 (GLOBE NEWSWIRE) -- E-Power Inc. (“E-Power”, the “Company”, “we” or “our”) (NASDAQ: EPOW), a global leader in energy storage battery anode materials and integrated...
-
T-Mobile Park updates cover 11,300+ square feet of digital canvas in the outfield for video, replays and more BROOKINGS, S.D., March 25, 2026 (GLOBE NEWSWIRE) -- Continuing to evolve the digital...
-
Tevogen regains compliance with Nasdaq minimum bid price requirement.
-
GIG HARBOR, Wash., March 25, 2026 (GLOBE NEWSWIRE) -- IP Strategy Holdings, Inc. (Nasdaq: IPST) (the “Company”) today highlighted the continued growth of tokenized K-culture assets through WITCH and...
-
Realbotix Humanoid Robot — Ericsson’s First Enterprise Robotics Client — Featured as Live Connected Endpoint in Pre-Standard 6G Over-the-Air Trial at Ericsson’s U.S. Headquarters; Onconetix Has...
-
IBG Acquires 51% stake in BlockFuel Energy as business combination nears completion Once complete, the combined entity will become a rising oil producer and power generation company with near-term...
-
First new FDA-approved treatment option in nearly 20 years for families living with this rare lysosomal storage diseaseFirst FDA-approved medicine in emerging new class of biotherapeutics that...
-
Phase 2b results for GH001 in TRD now published and peer-reviewed in JAMA Psychiatry New peer-reviewed article in forthcoming issue of Psychopharmacology Bulletin demonstrates that GH001 efficacy is...